Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2026
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events MAA Approval In January 2025, the European Medicines Agency (“EMA”) validated the Company’s Marketing Authorisation Application (“MAA”) for processing. On April 29, 2026, the European Commission granted marketing authorization for XOLREMDI® (mavorixafor) capsules for the treatment of patients with WHIM syndrome in the European Union.